Varicella zoster virus in bell's palsy: a prospective study  by Oliveira Santos, Mônica Alcantara de et al.
370
Brazilian Journal of otorhinolaryngology 76 (3) May/June 2010
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Varicella zoster virus in bell’s palsy: a prospective study
Abstract
Mônica Alcantara de Oliveira Santos 1, Hélio H. Caiaffa Filho 2, Melissa Ferreira Vianna 3, Andressa 
Guimarães do Prado Almeida 4, Paulo Roberto Lazarini 5
 1 ENT; Graduate Student (MSc) - School of Medical Sciences - Santa Casa de São Paulo.
 2 PhD; Professor; Technical Director of the Molecular Biology Lab Service - Central Lab - University Hospital - Medical School of the University of São Paulo (FM-USP)..
 3 MSc. PhD student - School of Medical Sciences Santa Casa de São Paulo.
 4 MD; ENT; Former Resident from the ENT Department - Santa Casa de Misericórdia de São Paulo.
 5 PhD; Assistant Professor of Otorhynolaryngology - Santa Casa de Misericórdia de São Paulo.
Paper submitted to the BJORL-SGP (Publishing Management System – Brazilian Journal of Otorhinolaryngology) on  July 19, 2009; 
and accepted on August 24, 2009. cod. 6514
Although Bell’s palsy is the major cause of acute peripheral facial palsy, its pathogenesis remains 
unknown. Reactivation of the varicella zoster virus has been implicated as one of the main causes 
of Bell’s palsy, however, studies which investigate the varicella zoster virus reactivation in Bell’s 
palsy patients are mostly Japanese and, therefore, personal and geographic characteristics are quite 
different from our population. 
Aims: To determine varicella zoster virus frequency in saliva samples from patients with Bell’s 
palsy, using PCR. 
Material and Method: One hundred seventy one patients with acute peripheral facial palsy were 
prospectively enrolled in this study. One hundred twenty were clinically diagnosed with Bell’s palsy, 
within one week of onset of the disease and no previous anti-viral therapy. We had 20 healthy adults 
as controls. Three saliva samples were collected from patients and controls at initial examination and 
at one and two weeks later. The detection of the varicella zoster virus DNA was performed using PCR. 
Results: Varicella zoster virus was detected in two patients (1.7%). The virus was not identified in 
saliva samples from the controls. 
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INTRODUCTION
Peripheral Facial Palsy (PFP) was described by Sir 
Charles Bell (1774-1842) in 1821. Initially, all cases of facial 
nerve paralysis were called Bell’s palsy (BP). Notwithstan-
ding, after the causes of the disease were discovered, only 
the idiopathic cases were called Bell’s palsy.
In studies about PFP, BP is the most common clini-
cal presentation1-3. Its incidence was estimated in 20 to 30 
cases for every 100,000 people4-6. Although it is the most 
frequent type of PFP, the cause of BP is still the object of 
many questions and theories.
The Varicella Zoster Virus (VZV) was one of the first 
viruses to be associated with the PFP. Back in 1907, James 
Ramsay Hunt described PFP manifestations and the typical 
skin lesions (vesicles and bubbles) on the skin of the ear 
conchae, frequently associated with tinnitus and vertigo. 
This clinical picture caused by the VZV started to be called 
Ramsay Hunt Syndrome (RHS), in homage to the author7.
Usually, the skin lesions crop up before the PFP; 
nonetheless, in 14% of the cases this happens afterwards, 
and may be absent in some individuals8. These cases of 
VZV-caused PFP and without skin manifestation have been 
called zoster sine herpete (ZSH).
In 1991, Dlugosch9 et al. described the VZV de-
tection technique through the polymerase chain reaction 
(PCR) test. Such technique drove new publications which 
confirmed the presence of the herpes virus in cases of 
PFP, among them: Furuta et al.10, who used an oropha-
rynx swab; Murakami et al.11, PCR in ear skin exudate; 
Pitkäranta et al.12, tear PCR; Furuta et al.13 and Lazarini et 
al.14, PCR in the saliva.
McCormick15 was the first to propose the theory 
of viral reactivation, according to which, after an initial 
infection the virus would pass through the blood current 
or the axon in a retrograde way, all the way to the sen-
sitive ganglia and there they remain latent16-18. The viral 
reactivation happens through a reduction of the immune 
activity which could be triggered by metabolic alterations15, 
surgical or dental procedures19,20 or event under stress or 
immunesuppression21.
The viruses, when reactivated, replicate and spread 
through the facial nerve and its branches, causing the in-
flammatory process which culminates with the PFP. One 
of the facial nerve branches, the chorda tympani nerve res-
ponsible for innervating the submandibular and sublingual 
glands, would also receive these reactivated viruses and, 
when stimulating salivation, it would make possible for 
these agents to pass to the saliva. In the saliva it would be 
possible to identify the viral DNA by means of the PCR14.
Of course that knowing the causing agent and 
identifying the cause for the BP would guide us not only 
in our approach, but also regarding a better treatment for 
our patients with PFP. Unfortunately most of the papers 
which discuss the VZV prevalence in saliva as a biologic 
agent of BP, do it in regards of the Japanese population, 
which establishes a population group and geographic 
characteristics which are very different from those of our 
population.
In general, the prevalence of the herpes virus is 
not the same throughout the world, there are variations 
between countries22,23 and regions24. The very prevalence 
of PFP is also variable. In Madrid, the annual incidence 
was estimated to be 24.1 per 100 thousand people25. In 
Sicily26, the prevalence was 642.8 per 100 inhabitants, 
almost thirty times larger.
These epidemiological variations in viral manifesta-
tion can cause a different etiological profile for BP in our 
settings, and such fact has not been studied yet.
Based on this reality, it is important to study the 
relationship between BP and the varicella zoster virus, 
describing its frequency and characteristics in our settings. 
Thus, the goal of our paper was to study the frequency of 
the varicella zoster virus in the saliva of individuals with 
Bell’s Palsy using PCR.
MATERIALS AND METHODS
This was a prospective study carried out in a tertiary 
hospital, which was submitted and approved by the Ethics 
Committee for Research with Human Beings of the present 
institution (Project 080/06).
We prospectively assessed 120 patients seen in the 
Department of Otorhinolaryngology and clinically diag-
nosed as BP bearers, from August of 2002 and October 
of 2007, according with the following inclusion criteria:
a) Acute PFP;
b) Symptom onset of up to one week prior to the 
date of the first medical visit;
c) Clinical and otorhinolaryngological exam without 
evidence of other causal factors for the paralysis;
d) No treatment with antiviral drugs.
The control group was made up of 20 adults without 
otological, neurotological alterations or acute infections.
In the first visit, the patients were submitted to an 
interview and general physical and otorhinolaryngological 
exam. They were all referred to weekly evaluations in order 
to follow up the paralysis symptoms, which was measured 
according to the House-Brackmann scale27,28.
Upon admission, BP patients and controls were 
submitted to saliva collection from the mouth floor using 
a disposable 5ml syringe without needle. The saliva was 
stored in a proper container for PCR (Ependorf).
We carried out tests to detect the VZV DNA by me-
ans of the traditional PCR using the VVZ-7 (5´ ATG TCC 
GTA CAA CAT CAA CT 3´/5´CGA TTT TCC AAG AGA 
GAC GC 3´) primers previously described for this virus.
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RESULS
We assessed 171 patients with PFP from August 
of 2002 to October of 2007. Of these, 120 fit the pre-
established inclusion and exclusion criteria.
Of the 120 patients in the study, 64 (53.3%) were 
females and 56 (46.7%) were males. Age varied between 
three and 80 years, with a mean value of 37.55 (±17.36) 
years.
VZV was studied through the PCR technique, and it 
was found in two patients with BP (1.7%, with a prevalen-
ce confidence interval ranging between 0.2% and 5.9%).
In the control group we did not find VZV DNA in 
any of the samples.
This difference regarding PCR positiveness between 
the cases and controls, although present was not statis-
tically significant, as shown by the Fisher’s exact test p= 
0.734 (Table 1).
relation associated with these findings.
First of all, no control group sample was positive. 
Quoting Murakami et al.29: “the positive result means 
only that the virus is present, which leads us to believe 
in reactivation because of the fact that the controls were 
all negative”.
In second, one of the patients had two positive 
results for VZV. This tells us that the positiveness was 
not random or the result of contamination, suggesting an 
association of the PFP to the virus presence in the saliva.
Compared to findings from the international lite-
rature, the frequency of the VZV found in BP patients in 
our population was considered low.
Furuta et al.10 found six VZV-positive patients in 
the PCR from the oropharynx swab of 36 BP patients. The 
authors collected from one to four samples per individual, 
and they did not explain the criteria used to choose the 
number of samples. It may be that since they collected 
more samples from each patient, they had more positive 
findings.
This same Japanese group19 described VZV positive-
ness through PCR in 23 of the 26 patients (88%) who had 
BP and were seronegative for VHS. In the initial sample 
of patients with BP, 82% of the patients had serological 
alterations regarding VHS; thus, this study was held with 
a restricted number of individuals with BP (18% only).
Furuta et al. 19 and Kawaguchi et al.30 found greater 
positiveness for VZV with the use of serology, if compared 
to the PCR. We would need studies comparing the two 
techniques for VZV in patients with BP.
The results from the present study are different 
from the ones found by Pitkäranta et al.12, who showed 
10% of VZV positiveness. Nonetheless, the authors used 
tears, making it even more difficult to compare the studies.
Furuta et al.31, quantified the VZV copies and no-
ticed that the viral load had a peak close to the day of 
the skin lesions manifestation. It is suggested that some 
negative PCR results for VZV could correspond to the 
drop in viral load.
Furuta et al.32, observed patients with SRH and 
described a patient with only one small oropharyngeal 
lesion who was not VZV-positive. We could argue that 
the lower the disease manifestation, the lower is the posi-
tiveness found in the PCR. In the present paper, since all 
the patients with some manifestation of the herpes disease 
were taken off the study, we would expect to find a lower 
positiveness, as it was the case.
All frequency differences may have happened 
because of the different population characteristics, which 
include both a racial or biological predisposition, as well 
as an association with the medium.
These data corroborate the Idea that the population, 
geographic and cultural differences can lead to different 
epidemiological manifestations of BP; and it is necessary 
to carry out regional studies.
Table 1. Results from the viral DNA in VZV, through the PCR tech-
nique, in saliva from 120 patients with Bell’s palsy and 20 control 
cases.
 VZV Total
  PCR positive  PCR negative  
BP 2 118 120
Controls 0 20 20
Total 2 138 140
BP = Bell’s Palsy VZV = Varicella Zoster Virus PCR = Polymerase 
chain reaction
Description of the PCR positive cases for VZV
1) Male, 62 years old with PFP on the left side, one 
day after hospital admission. The palsy degree at this time 
was HB VI. In this first assessment, saliva was collected 
from the patients, where the VZV was detected. The patient 
no longer returned to our clinic for future visits.
2) Male, 62 years old, with right side PFP, 12 hours 
after hospital admission. The palsy degree in the first visit 
was HB IV. We collected saliva from the patient in this 
first visit, from where we detected the VZV. The patient 
returned after one week, maintaining the same level of 
palsy and we chose to do a new saliva collection in order 
to confirm the results found. This second sample also 
showed VZV DNA. After four weeks the patient returned 
and we noticed palsy level HB III.
DISCUSSION
We found two patients with positive PCR for VHS. 
Although such result is not statistically significant, two 
factors lead us to believe that there could be an etiological 
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It is known that there is great difficulty in esta-
blishing the pros and cons of using antiviral drugs. Two 
of the main studies which assess the efficacy of antiviral 
drugs, one of them is Japanese33 and the other one is En-
glish34, yielded opposite results. This difference may have 
happened thanks to the diversity of factors which charac-
terize the populations studied, which makes it difficult to 
establish a global treatment approach.
The present study shows that the viral reactivation 
frequencies are still not studied enough in the West. The 
goal of describing these incidences in our settings was to 
check the importance of the viruses studied in our popu-
lation, so that based on these numbers we can establish 
better assessment and treatment protocols for our popu-
lation of patients with BP.
CONCLUSION
We noticed a frequency of 1.7% of VZV in saliva 
samples of patients with Bell’s palsy by means of the PCR 
technique.
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